CYTEK BIOSCIENCES, INC. financials

CTKB CIK 0001831915

Source: EDGAR filings · Built 2026-06-02T02:45:33Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -8.77M 21.85M 633.00K -21.98M 266.00K 13.61M
EBITDA -32.80M -13.31M -21.80M 688.00K 10.40M 14.26M
Working Capital 314.19M 328.78M 335.83M 404.98M 398.55M 182.09M
Net Debt -73.93M -87.41M -155.38M -281.36M -364.62M
Gross Margin 51.84% 55.43% 56.69% 61.56% 61.86% 55.70%
Operating Margin -20.04% -10.24% -14.43% -1.10% 7.16% 14.71%
Net Margin -33.02% -3.00% -6.29% 1.51% 2.37% 20.91%
Return on Equity (ROE) -19.47% -1.52% -3.09% 0.58% 0.75% -121.11%
Return on Assets (ROA) -14.42% -1.21% -2.46% 0.48% 0.65% 8.82%
Current Ratio 5.04× 5.86× 6.97× 9.26× 13.01× 7.86×
Debt-to-Equity 0.05× 0.03× 0.03× 0.04× 0.00×
Effective Tax Rate -122.98% -5.61% 22.67% -97.14% 49.02% -34.52%
Cash Conversion Ratio 0.07× -4.22× -0.43× -4.92× 1.53× 0.78×
Accruals Ratio -0.13× -0.06× -0.04× 0.03× -0.00× 0.02×
SBC % of Revenue 12.20% 13.39% 11.42% 10.12% 5.15% 0.66%
CapEx Coverage -1.15× 7.20× 1.14× -1.25× 1.06× 9.80×
Free Cash Flow Per Share $-0.07 $0.17 $0.00 $-0.16 $0.00 $0.42

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/E Trailing (Diluted) 510.50×
P/FCF 38.79× 1940.43× 4945.45×
FCF Yield 2.58% 0.05% 0.02%
EV / EBITDA 1599.89× 174.84×
P/S 3.22× 4.18× 6.18× 8.43× 17.06×
P/B 1.90× 2.12× 3.03× 3.25× 5.38×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 201.49M 200.45M 193.01M 164.04M 127.95M 92.84M
Revenues 193.01M 2.96M 2.18M 710.00K
Cost of Goods and Services Sold 97.03M 89.35M 83.59M 63.06M 48.81M 41.13M
Gross Profit 104.46M 111.11M 109.43M 100.97M 79.14M 51.71M
Research and Development Expense 36.47M 39.40M 44.15M 34.86M 24.44M 13.69M
Operating Expenses 144.84M 131.63M 137.27M 102.78M 69.99M 38.05M
Operating Income (Loss) -40.38M -20.52M -27.84M -1.80M 9.16M 13.66M
Income Tax Expense (Benefit) 36.70M 320.00K -3.56M -1.22M 2.91M -4.98M
Net Income (Loss) Attributable to Parent -66.54M -6.02M -12.15M 2.48M 3.03M 19.41M
Earnings Per Share, Basic $-0.09 $0.02 $0.00 $0.11
Weighted Average Number of Shares Outstanding, Basic 127.75M 130.61M 135.28M 134.51M 76.74M 29.13M
Earnings Per Share, Diluted $-0.09 $0.02 $0.00 $0.10
Weighted Average Number of Shares Outstanding, Diluted 127.75M 130.61M 135.28M 138.56M 81.54M 32.60M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 90.85M 98.72M 167.30M 296.60M 364.62M 165.23M
Assets, Current 392.00M 396.45M 392.06M 454.02M 431.73M 208.62M
Assets 461.54M 499.50M 494.46M 519.48M 463.31M 219.98M
Liabilities, Current 77.80M 67.66M 56.23M 49.04M 33.18M 26.54M
Liabilities 119.80M 103.76M 101.39M 93.93M 57.92M 41.69M
Stockholders' Equity Attributable to Parent 341.74M 395.74M 393.06M 425.55M 405.38M -16.03M
Common Stock, Shares, Outstanding 128.55M 129.21M 130.71M 135.37M 133.75M 31.24M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -4.69M 25.38M 5.28M -12.23M 4.63M 15.16M
Payments to Acquire Property, Plant, and Equipment 4.08M 3.52M 4.65M 9.75M 4.36M 1.55M
Net Cash Provided by (Used in) Investing Activities 10.12M -82.97M -93.89M -55.91M -20.99M -1.55M
Payments for Repurchase of Common Stock 15.07M 21.61M 44.15M 0 0
Net Cash Provided by (Used in) Financing Activities -13.43M -15.82M -41.81M 5.51M 213.56M 122.61M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CTKB CIK 0001831915), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

HD

THE HOME DEPOT, INC.

RCMT

RCM TECHNOLOGIES, INC.

ASRV

AMERISERV FINANCIAL INC /PA/